GASTROENTEROLOGY, cilt.146, sa.4, ss.980-989, 2014 (SCI-Expanded)
BACKGROUND & AIMS: Tenofovir disoproxil fumarate (TDF) is active against lamivudine-resistant hepatitis B virus (HBV) infection, but data to support its clinical efficacy in this setting are limited.